European Union Approves Janssen Ebola Vaccine
July 02 2020 - 8:37AM
Dow Jones News
By George Mwangi
Special to Dow Jones Newswires
The European Commission has granted marketing authorization to
pharmaceutical company Janssen for a new Ebola vaccine, developed
in partnership with the University of Oxford, the British
university said Thursday.
The two-dose Ebola vaccine regimen, developed by Johnson &
Johnson's Janssen, is specifically designed to induce long-term
immunity against the Ebola virus in adults and children aged one
year and above, the university said.
The Ebola vaccine has already been deployed in the North Kivu
region of the Democratic Republic of the Congo and Rwanda, it
added.
Write to Barcelona Editors at barcelonaeditors@dowjones.com
(END) Dow Jones Newswires
July 02, 2020 08:22 ET (12:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
